title: [Effectiveness of anticoagulant oral treatment in patients with thrombus in left ventricle after acute myocardial infarction].
abstract: Left ventricular mural thrombi (LVMT) is a complication of acute myocardial infarction (AMI), that may produce peripheral embolism which could be fatal. In order to establish an adequate time of oral anticoagulant (OA) therapy, we undertook a prospective study that included 45 patients with AMI and left ventricular thrombi detected by echocardiographic study, in the first 5 to 10 days postinfarction, the study was repeated, in 3 and 6 months. Treatment with oral anticoagulant was initiated at the point of the detection of thrombi maintaining an INR of 1.5 to 2. Thirty nine patients (79%) were males and 6 (11%) were females, with an age of 29 to 85 years and a range of 62 +/- 11 years. Forty four patients (98%) presented anterior wall infarction and 1 (2%) posteroinferior infarction. In patients with anterior infarction, in 38 (85%) the thrombi was located at the apical wall (p < 0.05), 5 (11%) in the septal wall and other (2%) in anterior and apical walls. The patient with the posteroinferior infarction presented extension to the right ventricle, where the thrombus was located (2%). The contractility alterations related with thrombi were diskinesia, followed by hipokinesia and finally akinesia. The ejection fraction had not relationship with thrombi formation. LVMT dissolved in 32 patients (71%) at 3 months (p < 0.05), in 8 (18%) in 6 months and in 5 (11%) it was maintained for more than 6 months. None of the patients presented complications of OA. We conclude that the LVMT are more frequent in anterior infarctions, essentially in those that present diskinesia. The majority of LVMT are resolved in 6 months with OA therapy.
authors.affiliation: División de Cardiología, Hospital de Especialidades Centro Médico La Raza, Instituto Mexicano del Seguro Social, México, D.F.
authors.forename: A M
authors.initials: AM
authors.lastname: Carrillo
authors.forename: A
authors.initials: A
authors.lastname: Valdespino
authors.forename: S
authors.initials: S
authors.lastname: Solorio
authors.forename: E
authors.initials: E
authors.lastname: Badui
authors.forename: R
authors.initials: R
authors.lastname: Enciso
authors.forename: L
authors.initials: L
authors.lastname: Lepe
authors.forename: A
authors.initials: A
authors.lastname: Lara
authors.forename: S
authors.initials: S
authors.lastname: Ocampo
authors.forename: R
authors.initials: R
authors.lastname: Alonso
authors.forename: M A
authors.initials: MA
authors.lastname: Romero
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D006331:Heart Diseases / Q000188:drug therapy* / Q000209:etiology; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications*; D011446:Prospective Studies; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D006493:Heparin